Edition:
India

People: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

5.23USD
23 Oct 2020
Change (% chg)

$0.06 (+1.16%)
Prev Close
$5.17
Open
$5.22
Day's High
$5.25
Day's Low
$5.07
Volume
14,118
Avg. Vol
67,626
52-wk High
$15.60
52-wk Low
$3.41

McIntyre, Gail 

Dr. Gail F. McIntyre Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. McIntyre has served as the Company’s Chief Scientific Officer since February 2019. Dr. McIntyre also served as the Company’s Senior Vice President of Research and Development from October 12, 2018, when the Company, then known as Versartis, Inc., and Aravive Biologics, Inc. (“Private Aravive”), completed a merger and reorganization (the “Merger”), pursuant to which Private Aravive survived as the Company’s wholly owned subsidiary, until February 2019 and served as Private Aravive’s Senior Vice President of Research and Development from January 2017 to October 2018 and a consultant to Private Aravive from August 2016 until January 2017. Having brought multiple drugs to market, Dr. McIntyre has more than 25 years of experience in drug development, strategic business development, licensing and M&A activities. Dr. McIntyre has served as a principal at IntelliDev Consulting, LLC providing consulting services to several biotechnology companies for three years, while also serving as Vice President of Development for Meryx, Inc. from January 2014 until January 2016. Prior to that, Dr. McIntyre held the position of Senior Vice President of Research at Furiex Pharmaceuticals, Inc. and previously served as head of PPD’s compound partnering business. At both Furiex and PPD, she strategized and managed all preclinical and clinical activities for drug development programs and was responsible for identification of new partnering opportunities and technical due diligence for both in-licensing opportunities and new business acquisitions. At PPD, she led the partnering and the in-licensing of Alogliptin from Syrrx, Inc. at pre-IND stage and the licensing to Takeda at Phase 2. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

Basic Compensation

Total Annual Compensation, USD 325,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 388,495
Fiscal Year Total, USD 713,495

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --